The peptide world is moving faster than the FDA. The Protocol gives you the truth. Backed by science and studies. Not trying to sell you a product. No vendor pitches. No magic-bullet claims. No fluff.
Check your inbox. First issue lands next Tuesday at 6 AM ET.
Every issue, same rhythm. Ten sections covering the science, the news, the stacks, and the things nobody else writes about. Four minutes to read. Save it forever.
The most important news of the week: FDA pathway updates, Phase 3 readouts, policy moves. Neutral reporter tone, primary sources cited.
Mechanism, half-life, who it's for, what people actually report. Built from reader replies. The most-requested peptide wins the slot every week.
Fresh peer-reviewed research, summarized tight, sourced to PubMed and journal names. The research curation you'd do yourself if you had the time.
A real research stack discussed in community literature: research goal, compounds covered, mechanism sequencing, and the published evidence each piece is built on.
Industry purity alerts, failed third-party tests, COA red flags. The section that gets The Protocol forwarded.
Obscure peptide history, one reader question answered with first-name credit, and one non-peptide longevity concept that compounds over time.
This is what a real issue looks like. Issue 001 leads with Retatrutide's Phase 3 readout, three new studies you missed, a research stack discussion, a Vendor Watch on Reta purity, and a deep cut on glucagon's 100-year history. Subscribe to get the full issue plus everything that follows.
Plus three studies you missed, a stack the community is running right now, and the vendor red flag nobody's talking about.
Full issue covers Peptide of the Week (Reta decoded), In the Lab (Tesamorelin, BPC-157, GHK-Cu studies), Stack Spotlight (a research framework discussion), Vendor Watch (Reta purity problem), Deep Cut (glucagon's 100-year history), Reader Q, and The Long Game (the free peptide).
The Protocol is published by NLL Labs, a research peptide vendor with public third-party testing. The newsletter is free education, separate from the shop. Compounds get covered whether NLL carries them or not. Every claim has a citation. Every compound discussed has primary sources.
These are likely Peptide-of-the-Week candidates over the next two months. Subscribers vote with every reply. Most-requested compound wins the slot each Tuesday. If you want a peptide bumped to the front, hit reply.
Short answers. No fluff.
Ten sections, four minutes, every Tuesday at 6 AM ET. Pure education, published by a lab with public lab reports. Free forever.
Check your inbox. First issue lands next Tuesday at 6 AM ET.